DNA Methylation Market Size, Share & Trends Analysis Report By Technology (PCR, Microarray, Sequencing), By Application (Gene Therapy, Diagnostics), By Product, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global DNA methylation market size was valued at USD 1,242.5 million in 2021. It is expected to expand at a compound annual growth rate (CAGR) of 14.67% from 2022 to 2030. The increasing cases of cancer globally remains the primary driver of its anticipated growth. Furthermore, the declining cost of treatment with streamlining of product approvals also remains a steady driver of growth. Furthermore, significant government support for research and development activities with direct funding continues to open new opportunities for growth. DNA methylation remains a promising technique to advance research in core areas of chronic disease treatment. In September 2022, researchers from the University of California published a journal in Nature Communications stating the potential application of cell-free DNA methylation as a promising biomarker for cancer detection at an early stage.

The COVID-19 outbreak impacted the market negatively due to  movement restrictions, which hindered research and testing at research centers and laboratories. However, post-pandemic, reopening of research institutions resulted in increased usage of DNA methylation. Moreover, the accessibility of a broad range of test kits has further created significant opportunities for market players. For instance, in June 2022, Boca ScientificInc. announced expansion of its product portfolio by adding MethylDetect DNA Methylation Assay Kits. These factors continue its robust adoption at research institutes and various pharmaceutical and biotechnology companies.

The DNA methylation analysis technique helps scientists gain valuable insights into gene regulation and potential biomarkers identification. Abnormal DNA methylation has been associated with several disease processes, such as obesity, cancer, and others. It also promises potential application in agronomic research to study responses to temperature extremes, drought, and other environmental changes. In June 2022, a research article published in MDPI stated that DNA methylation is mostly studied in epigenetic marks in plants and other eU.K.aryotes. It is considered as a sustainable source of variation contributing to crop production and health.

Furthermore, various high-throughput technologies such as microarrays and next-generation sequencing (NGS) have facilitated studies related to genome-wide methylation profiling. These technologies offer ways to understand DNA methylation significance, providing insights into the functional effects of variation. For instance, in February 2021, Twist Bioscience launchedNGS Methylation Detection System, which is to be used for the analysis of liquid biopsy cancer and epigenetic studies. This would further provide insight into disease pathology.

Technology Insights

Sequencing segment captured the highest market share in 2021 due to the rapid advancement in technologies that offer cost-effective, accurate, and quick results. Bisulfite genomic sequencing is considered a gold-standard technology. Researchers have employed whole-genome bisulfite sequencing to understand the epigenetic landscape of immune-related disorders caused by tobacco use. Growth of this technology in research studies to understand the adverse effects of smoking and how it relates to diseases promises further growth opportunities in the segment.

PCR is anticipated to witness significant growth in the coming years owing to an increase in its use in diagnostics and DNA sequencing procedures. During Covid-19, the demand for PCR technology significantly increased in relevance as a diagnostic procedure. PCR-based methods are primarily used to analyze DNA methylation on a gene-by-gene basis. In May 2022, Pentabase A/S announced the launch of a qPCR-based assay, EpiDirect, for detecting DNA methylation without pre-treatment. This product aims to create a cancer screening technique that can detect cancers in cell-free DNA environment.

Product Insights

The consumables segment dominated the DNA methylation market in 2021, as it is majorly used in the DNA sequencing procedures and diagnosis process. Growing demand for quick turnaround times and high throughput results are also strong contributors to the growth. A wide range of consumables are used in the research industry, which includes tubes, vials, microarray panels, dispensers, and pipette tips. High volume requirements of these consumables continue to boost the overall demand in the market. In April 2022, PacBio announced of expansion of its product offering by adding new DNA methylation consumables. These are made directly available to all itscustomers usingSequel II and Sequel IIe systems.

The enzyme segment is anticipated to witness lucrative growth in the coming years due to the increasing demand for protein-modifying and enzymes in the DNA methylation technique. These are widely used in agrigenomic research, genomic research, and genome-wide analysis. The usage of enzymes in DNA methylation reactions during sequencing analysis, such as Illumina sequencing and pyrosequencing remains prominent. Moreover, the utilization of next-generation sequencing technology has bolstered the demand for enzymes in the biotechnology industry.

Application Insights

Clinical research segment captured the highest market share in 2021, thanks to the increasing number of clinical trials for several diseases globally. Furthermore, increased R&D expenditure, and increasing demand for potential biomarkers promises more growth opportunities. In July 2020, an article published in Springer stated that disease-linked methylation changes could be used as biomarkers at all clinical disease management stages. These various stages include predisposition and risk assessment screening through early diagnostics to the personalized patient care of chronic and relapse disease. Therefore,disease-relate discovery is a promising biomarkers and a potential gamechanger for precision medicine.

Diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 15.86%.DNA methylation profiling is an emerging tool that promises to increase the accuracy of pathological diagnosis. In January 2022, an article published in PubMed stated that DNA methylation patterns in circulating tumor DNA (ctDNA) offer considerable promisefor the categorization and detection of cancer with the least invasive approach. Methylation profiling can be widely used as a cancer diagnostic tool for all tumor types, despite its recent arrival to the scene.

End-use Insights

Pharmaceutical and biotechnology end-use segment captured the highest market share in 2021. The increased adoption of DNA methylation in the field of molecular biology and genomics remains the primary driver of this growth. Moreover, increasing usage of high throughput technologies such as NGS by key market players also continues to open new opportunities for growth. In June 2020, Base Genomics announced of leveraging TET-assisted pyridine borane sequencing (TAPS) technology developed by the University of Oxford to find epigenetic signs of cancer in the blood.

Research and Academia is anticipated to witness significant growth in the coming years owing to increased R&D in the epigenetics sector. This along with increasing government support in terms of funding remains promising drivers of growth.

In July 2022, according to a study published in Genome Biology, DNA methylation in bacteria controls reproduction, gene expression, and pathogenicity. The tissue-specific gene expression that regulates a cell's identity, such as if it’s a brain cell or a skin cell, is regulated by DNA methylation Quality research remains the backbone of growth in the market.

Regional Insights

North America accounted for the largest market share in 2021. This can be attributed to the large network of manufacturing and R&D facilities, the increase in product launches and approvals. Moreover, the growing demand for protein expression systems has also contributed significantly to the regional growth.

In May 2022, Twist Bioscience introduced a human methylome panel to allow methylation fractions to be detected in a wide range of applications. This supports the identification of epigenetic targets and the discovery of differentially methylated areas for human development and cancer metastasis research.

Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to growing support from the government with several initiatives. Furthermore, the growing focus of global players on emerging markets of Asia Pacific also remains a promising driver of growth.

In September 2020, AnchorDxentered announced of developing liquid biopsy diagnostic model for breast cancer detection at an early stage. This diagnostic model is focused on circulating cell-free DNA-based methylation patterns. Similarly, in August 2022, Oncgnostics GmbH received authorization from the Chinese government to market its GynTect test to doctors and patients. This is the first methylation test to be authorized in China for the triage cervical cancer cases.

Key Companies & Market Share Insights

Key players operating in the DNA methylation industry are taking several initiatives such as strategic collaborations, partnerships, and geographical expansion in emerging regions. For instance, in June 2020, Foundation Medicine, Inc acquired Lexent Bio, Inc. to expand the company’s liquid biopsy platforms to improve patient cancer care. This novel technique can be used to chronicle the progression of cancer in a diverse population of patients. Some prominent players in the global DNA methylation market include:

• New England Biolabs

• Sysmex Corporation

• Abcam plc.

• F. Hoffmann-La Roche Ltd.

• Diagenode Diagnostics S.A.

• Thermo-Fisher Scientific Inc.

• Agilent Technologies Inc.

• BioRad Laboratories Inc.

• Exact Sciences Corporation

• QIAGEN N.V.

• Active Motif, Inc.

• Illumina Inc.

• EpiGentek Group Inc.

• Pacific Biosciences Inc.

• New England Biolabs Inc.

• Merck KGaA

• Zymo Research Corporation

• PerkinElmer Inc.

DNA Methylation Market Report Scope

Global DNA Methylation Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global DNA methylation market report based on technology, application, product, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Polymerase Chain Reaction (PCR)

  • Microarray

  • Sequencing

  • Others

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

  • Kits & Reagents

  • Enzymes

  • Instruments & Software

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Gene Therapy

  • Clinical Research

  • Diagnostics

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital & Diagnostic Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Research & Academia

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE